Association of clinicopathological factor with lymph node metastasis in rectal cancer patients: a retrospective cohort study

Table 3 Comparative analysis of clinicopathological datas between LNM and non-LNM groups

Viable	non-LNM (95, 47.5%)	LNM (86, 52.5%)	P
Age(y)			0.229
≥65	46(48.4%)	34(39.5%)
<65	49(51.6%)	52(60.5%)
Sex			0.408
Male	62(65.3%)	51(59.3%)
Female	33(34.7%)	35(40.7%)
Location (cm)			0.091
≥ 5	71(74.7%)	73(84.9%)
< 5	24(25.3%)	13(15.1%)
T			0.001*
T1−2	38(40.0%)	15(17.4%)
T3-4	57(60.0%)	71(82.6%)
PNI			< 0.001*
Negative	67(70.5%)	24(27.9%)
Positive	28(29.5%)	62(72.1%)
LVI			< 0.001*
Negative	73(76.8%)	21(24.4%)
Positive	22(23.2%)	65(75.6%)
TDs			0.012*
Negative	89(93.7%)	70(81.4%)
Positive	6(6.3%)	16(18.6%)
TLN (average ± SD)	18.2 ± 6.2	20.2 ± 6.7	0.039*
CEA(ng/ml)			< 0.001*
≥5	25(26.3%)	46(53.5%)
<5	70(73.7%)	40(46.5%)
CA199 (ng/ml)			0.010*
≥27	12(12.6%)	24(27.9%)
<27	83(87.4%)	62(72.1%)
NLR			0.371
H-NLR	18(18.9%)	21(24.4%)
L-NLR	77(81.1%)	65(75.6%)
PLR			0.001*
H-PLR	72(75.8%)	81(94.2%)
L-PLR	23(24.2%)	5(5.8%)

Data are presented as n (%),Bolded p-values indicate statistical significance at p < 0.05
Abbreviations: LVI: lymphovascular invasion; PNI: perineural invasion; CEA: carcinoembryonic antigen TDs: tumor deposits;
TNM: tumor node metastasis; NLR: neutrophil-to-lymphocyte ratio; PLR: platelet-to-lymphocyte ratio
TLN: total lymphnode number
using Fisher’s exact test or chi-squared test for categorical variables
a P-value was estimated by t test

ISSN: 1471-230X